Answers are grounded in this paper and cite their sources.
Randomized trial shows antitumor activity of nivolumab plus ipilimumab in metastatic castration-resistant prostate cancer, suggesting a prognostic biomarker for further study.
T cells), which was associated with prolonged overall survival. These results provide further evidence of antitumor activity with nivolumab plus ipilimumab in select patients with metastatic castration-resistant prostate cancer and nominate a candidate prognostic biomarker that warrants confirmation in future prospective clinical trials.
No takes yet. Share an insight, caveat, or question.
Sharma et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: